Martin David Harp

Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.

The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.

The module encompasses real world data on more than 250,000 de-identified patients and provides information on extracting diagnoses from clinical notes in electronic health records.

The collaboration will bring automated, AI-powered OCT segmentation to MICRON Software Suite.

Annual conference to kick off May 5 in Emerald City.

At this year's ASCRS meeting in Boston, Massachusetts, Josefina Botta, MD, MSc, discussed her real-world experiences with the RayOne EMV toric lens.

At this year's ASCRS meeting Rom Kandavel, MD, of Colvard-Kandavel Eye Center in Los Angeles, California discussed the paper he presented at the meeting, which focused on IOP lowering and medication burden for patients who received the iStent inject.

BVI lenses feature a unique C-loop haptic design, known as “POD,” introduced to the market with the launch of the PODEYE hydrophobic IOL in Europe in 2012.

A brief analysis showed that ChatGPT 3.5 performed better.

UPFs include fast food, energy drinks and soda, sweets such as chocolates and candies and much more.

At this year's ASCRS meeting, J. Morgan Micheletti, MD talked about myriad research projects he discussed at the meeting and also emphasized the importance of the Young Eye Surgeons (YES).

At this year's ASCRS meeting in Boston, Massachusetts, Pete England gave an update on ViaLase's development on the first femtosecond laser for the treatment of open-angle glaucoma.

At this year's ASCRS meeting in Boston, Massachusetts, Leonard Borrmann, CEO at Centricity Vision, about the company's new product ZEPTOLink, including first-in-human data.

Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment on macular degeneration-treated mice in space.

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.

Results showed LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, while LNZ101 showed similar results but ultimately failed to show superiority to LNZ100.

Rahul S Tonk, MD, MBA, sat down to discuss a roundtable discussion he had on DMEK and DSEK surgery at this year's ASCRS meeting held in Boston, Massachusetts, from Friday, April 5, to Monday, April 8, 2024.

Alejandro Espaillat, MD, sat down to discuss his presentation on pearls for the anterior segment surgeon at this year's ASCRS meeting held in Boston, Massachusetts.

Neda Nikpoor, MD, sat down to discuss her presentation on the single-site study on the effectiveness of a sterile model with two ALLYs, in two operating rooms against a model with only one laser for two rooms at this year's ASCRS meeting held in Boston, Massachusetts.

Ula Jurkunas, MD, sat down to discuss her presentation on the management of anterior corneal disease at this year's ASCRS meeting held in Boston, Massachusetts.

Roger Kennedy, director of marketing at BioTissue sat down to discuss the new products the company will be unveiling at this year's ASCRS meeting held in Boston, Massachusetts.

Jennifer Loh, MD, sat down to discuss her presentation on major eye issues that can interfere with refractive cataract surgery, specifically dry eye disease, at this year's ASCRS meeting held in Boston, Massachusetts.

The 2 organizations to receive initial gifts will be Sight for Life and Eye Corps.

The Osprey trial has started dosing while the Apteryx trial is anticipated to begin within the next few weeks.

Following the CRL from the FDA last year, Aldeyra is planning to initiate a dry eye chamber clinical trial in the first half of 2024.

Stargardt disease is the most common inherited retinal dystrophy (causing blurring or loss of central vision) in both adults and children.

The new cohort will add patients living with IRDs caused by mutations in multiple genes to the already existing cohort of patients with IRDs caused by single gene mutations.

Results from the trial by Nannodropper show microdrops could reduce waste, cost, and side effects while being as effective as traditional size drops.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R).